Improved multidetector asymmetrical-flow field-flow fractionation method for particle sizing and concentration measurements of lipid-based nanocarriers for RNA delivery.

Asymmetric-flow field-flow fractionation Frit-inlet channel Lipid-based nanoparticles Nanomedicine Particle concentration Particle size Physical–chemical characterisation RNA delivery

Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 03 11 2020
revised: 09 02 2021
accepted: 11 03 2021
pubmed: 23 3 2021
medline: 8 5 2021
entrez: 22 3 2021
Statut: ppublish

Résumé

Lipid-based nanoparticles for RNA delivery (LNP-RNA) are revolutionizing the nanomedicine field, with one approved gene therapy formulation and two approved vaccines against COVID-19, as well as multiple ongoing clinical trials. As for other innovative nanopharmaceuticals (NPhs), the advancement of robust methods to assess their quality and safety profiles-in line with regulatory needs-is critical for facilitating their development and clinical translation. Asymmetric-flow field-flow fractionation coupled to multiple online optical detectors (MD-AF4) is considered a very versatile and robust approach for the physical characterisation of nanocarriers, and has been used successfully for measuring particle size, polydispersity and physical stability of lipid-based systems, including liposomes and solid lipid nanoparticles. However, the unique core structure of LNP-RNA, composed of ionizable lipids electrostatically complexed with RNA, and the relatively labile lipid-monolayer coating, is more prone to destabilization during focusing in MD-AF4 than previously characterised nanoparticles, resulting in particle aggregation and sample loss. Hence characterisation of LNP-RNA by MD-AF4 needs significant adaptation of the methods developed for liposomes. To improve the performance of MD-AF4 applied to LNP-RNA in a systematic and comprehensive manner, we have explored the use of the frit-inlet channel where, differently from the standard AF4 channel, the particles are relaxed hydrodynamically as they are injected. The absence of a focusing step minimizes contact between the particle and the membrane, reducing artefacts (e.g. sample loss, particle aggregation). Separation in a frit-inlet channel enables satisfactory reproducibility and acceptable sample recovery in the commercially available MD-AF4 instruments. In addition to slice-by-slice measurements of particle size, MD-AF4 also allows to determine particle concentration and the particle size distribution, demonstrating enhanced versatility beyond standard sizing measurements.

Identifiants

pubmed: 33745980
pii: S0939-6411(21)00069-2
doi: 10.1016/j.ejpb.2021.03.004
pii:
doi:

Substances chimiques

Drug Carriers 0
Lipids 0
Pharmaceutical Preparations 0
RNA 63231-63-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-265

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

R Mildner (R)

Wyatt Technology, Hochstrasse 12a, 56307 Dernbach, Germany.

S Hak (S)

Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.

J Parot (J)

Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.

A Hyldbakk (A)

Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.

S E Borgos (SE)

Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.

D Some (D)

Wyatt Technology, 6330 Hollister Ave., Santa Barbara, CA 93117, USA.

C Johann (C)

Wyatt Technology, Hochstrasse 12a, 56307 Dernbach, Germany.

F Caputo (F)

Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway. Electronic address: fanny.caputo@sintef.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH